International Womens Day: Break the bias in pain research

On #InternationalWomensDay, let's recognize the persistent challenges in women's health that extend beyond healthcare into scientific research. Underrepresentation in R&D, from data collection to clinical trials, remains a concern, with diseases impacting women receiving less research funding.

In 2024, the International Association for the Study of Pain (IASP) is committed to emphasizing sex and gender disparities in pain research.

Endometriosis affects one in ten women worldwide. For many of them, everyday life is disrupted due to severe chronic and acute pain. Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients.

IASP Global Year 2024:

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.